Polaris Genomics
Polaris Genomics is pioneering a biologically-based approach to mental health care, focusing on the development of objective diagnostics and novel therapeutics through genomics and machine learning. Their mission is to enhance the understanding and treatment of mental health conditions, aiming for a future free from stigma and suffering.
Polaris Genomics
9841 Washingtonian Blvd., Suite 200, Gaithersburg, MD 20878, USA
What We Do
A genomics-based platform that curates information on biologically-relevant gene network pathways indicated in neuropsychiatric conditions.
A first-of-its-kind blood test for PTSD screening and triage that measures RNA expression levels of genetic markers associated with PTSD.
A targeted neuropsychiatric gene panel layered with a deep analytics engine and data repository to develop biomarker-based diagnostics and therapeutics for mental health conditions.
Psychological and Cognitive Health and Performance
Show More (2)Application Area
Key People
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Financial Officer
Director, Marketing
Director, Communications
News & Updates
Polaris Genomics is recruiting volunteers for a study using genomics to understand PTSD biology and develop a blood-based screening tool, PTS-ID™.
An article discussing the importance of RNA in biology and its relevance to mental health diagnostics and therapeutics, authored by Nobel laureate Dr. Thomas Cech.
Polaris Genomics has received a $100,000 grant from the IGNITE Startup Grant program to support its innovative work in mental health diagnostics.
Polaris Genomics was recognized in the Founder Institute's list of fastest growing companies, highlighting its advancements in genomics-based mental health diagnostics.